Alicia Villatoro

  • Postdoc; PhD, MSc

Kreftforeningen

Education:

2015-2022: PhD student in Molecular and Clinical Cancer Research, Department of Medical Biology, University of Tromsø (UiT) - The Arctic University of Norway, Norway. PhD thesis: “The role of interleukin-1 receptor antagonist in normal and malignant hematopoiesis”.

2012-2013: “Degree in Salamanca” (Research project), University of Salamanca, Spain. Dissertation: “Usefulness of an experimental model of obstructive cholestasis to investigate the role of phospholipase A2 in neonatal respiratory distress syndrome”.

2012-2013: Master in Cellular and Molecular Physiopathology and Pharmacology, University of Salamanca, Spain. Master thesis: “Neonatal respiratory distress syndrome”.

2007-2012: Bachelor in Biology, University of Salamanca, Spain.

2009-2013: Imaging for diagnosis, Radiology technician, I.E.S. Martínez Uribarri, Salamanca, Spain.

 

Research interests:

Implement cell therapy, especially immunotherapy (CAR T cells and T cell therapy) for the treatment of cancer.

Development of new immunotherapies (i.e. CARs) to attack the cellular origin of cancer, such as cancer stem and progenitor cells, and effectively eradicate neoplasms.

Hematological diseases, hematopoietic stem cell and their sorrounded microenvironment.

 

Work experience:

2015-2022: PhD student at the Department of Medical Biology of the University of Tromsø (UiT) - The Arctic University of Norway, Norway.

2017-2020: Affiliated with the Norwegian Center of Molecular Medicine (NCMM), Oslo, Norway.

2021: Affiliated with the Department of Biochemistry at the University of Oslo (UiO), Norway.

2014: Intern at the Institute of Molecular Biology (IMB), Mainz, Germany.

2012-2013: Intern at the Department of physiology and pharmacology of the University of Salamanca, Spain.

 

 
Page visits: 49